SQI Diagnostics announces agreement with Isis Pharmaceuticals

SQI Diagnostics announced that they have entered into a method development agreement with Isis Pharmaceuticals to develop a multiplexed assay that will utilize SQI’s Ig_PLEX multiplexing immunogenicity technology.